{"id":494,"date":"2004-05-11T00:00:00","date_gmt":"2006-07-28T00:48:59","guid":{"rendered":""},"modified":"2022-10-04T21:24:09","modified_gmt":"2022-10-05T01:24:09","slug":"controlling-drug-costs-for-people-living-with-hivaids-federal-regulation-of-pharmaceutical-prices-in-canada","status":"publish","type":"publication22","link":"https:\/\/www.hivlegalnetwork.ca\/site\/controlling-drug-costs-for-people-living-with-hivaids-federal-regulation-of-pharmaceutical-prices-in-canada\/","title":{"rendered":"Controlling Drug Costs for People Living with HIV\/AIDS: Federal Regulation of Pharmaceutical Prices in Canada"},"content":{"rendered":"<img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-2500\" alt=\"Controlling Drug Costs for People Living with HIV\/AIDS: Federal Regulation of Pharmaceutical Prices in Canada\" src=\"..\/wp-content\/uploads\/2013\/08\/Drug-Costs-ENG.jpg\" width=\"140\" height=\"180\" \/><br \/>\nThe paper:<\/p>\n<ul>\n<li>highlights the significance of policy on pharmaceutical pricing, given increasing costs and spending on medicines as part of overall healthcare spending in Canada;<\/li>\n<li>identifies recent developments that are important because they inform current debates in Canada over regulating drug prices, or our policies in general relating to pharmaceuticals;<\/li>\n<li>outlines current federal law and policy on the regulation of pharmaceutical manufacturers&#8217; prices; and, finally,<\/li>\n<li>makes recommendations for reform of federal regulation of pharmaceutical prices in Canada.<\/li>\n<\/ul>\n<p class=\"download-link-button\"><a class=\"download-link en\" title=\"Controlling Drug Costs for People Living with HIV\/AIDS: Federal Regulation of Pharmaceutical Prices in Canada\" href=\"https:\/\/www.hivlegalnetwork.ca\/site\/download\/10002\/?tmstv=1777600471\" rel=\"nofollow\">\r\n\tDownload<\/a><\/p>\n<!-- Richard Elliott; Controlling Drug Costs for People Living with HIV\/AIDS; Federal Regulation of Pharmaceutical Prices in Canada; healthcare spending; pharmaceutical pricing; Patented Medicine Prices Review Board; PMPRB; excessive pricing -->","protected":false},"author":1,"featured_media":0,"menu_order":0,"template":"","meta":{"_acf_changed":false,"footnotes":""},"publication_topics":[145],"publication_type":[179],"publication_language":[184,185],"class_list":["post-494","publication22","type-publication22","status-publish","hentry","publication_topics-access-to-medicines","publication_type-reports","publication_language-english","publication_language-french"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hivlegalnetwork.ca\/site\/wp-json\/wp\/v2\/publication22\/494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hivlegalnetwork.ca\/site\/wp-json\/wp\/v2\/publication22"}],"about":[{"href":"https:\/\/www.hivlegalnetwork.ca\/site\/wp-json\/wp\/v2\/types\/publication22"}],"author":[{"embeddable":true,"href":"https:\/\/www.hivlegalnetwork.ca\/site\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":11,"href":"https:\/\/www.hivlegalnetwork.ca\/site\/wp-json\/wp\/v2\/publication22\/494\/revisions"}],"predecessor-version":[{"id":22511,"href":"https:\/\/www.hivlegalnetwork.ca\/site\/wp-json\/wp\/v2\/publication22\/494\/revisions\/22511"}],"wp:attachment":[{"href":"https:\/\/www.hivlegalnetwork.ca\/site\/wp-json\/wp\/v2\/media?parent=494"}],"wp:term":[{"taxonomy":"publication_topics","embeddable":true,"href":"https:\/\/www.hivlegalnetwork.ca\/site\/wp-json\/wp\/v2\/publication_topics?post=494"},{"taxonomy":"publication_type","embeddable":true,"href":"https:\/\/www.hivlegalnetwork.ca\/site\/wp-json\/wp\/v2\/publication_type?post=494"},{"taxonomy":"publication_language","embeddable":true,"href":"https:\/\/www.hivlegalnetwork.ca\/site\/wp-json\/wp\/v2\/publication_language?post=494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}